Iridium complex-based double-metal-center radiodynamic drug and preparation method thereof
An iridium complex and kinetic technology, applied in the field of medicine, can solve the problems of limited enhancement effect and no large-scale clinical application, and achieve the effects of reducing the attenuation length, improving the energy transfer efficiency, and increasing the attenuation coefficient.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0032] In this embodiment, R1 is selected from phenyl, X is selected from nitrogen atom, R2 is selected from methyl group; M is selected from holmium(III) ion.
[0033] When R1 is selected from phenyl, X is selected from nitrogen atom, and R2 is selected from methyl group, the radiodynamic drug tetrakis[bis(2,3-diphenylquinoxaline)·2,2'- Bipyridine-4,4'-dicarboxylate iridium(III)]·bis(acetic acid)diholmium(III)(Ir-M-1).
[0034] Its synthetic chemical formula is as figure 1 Shown, concrete its preparation process is:
[0035] 1. Preparation of intermediate bridged chloroiridium complex (Ir-1):
[0036] 2,3-diphenylquinoxaline (310.6mg, 1.1mmol) and IrCl 3 Hydrate (60% Ir, 160mg, 0.5mmol) was added to 5mL of H 2 O and 15mL of 2-methoxyethanol in a mixed solvent, then reflux and stir for 24h under the protection of an inert gas (argon). After cooling down to room temperature, add 5 mL of H 2 O, the ice bath was further cooled until a large amount of brown precipitates were...
Embodiment 2
[0042] Verification of X-ray absorption effect of radiodynamic drug (Ir-M-1) in solid state:
[0043] The Ir-2 and Ir-M-1 solid powders described in Example 1 are respectively placed in a 1mL centrifuge tube, and the emission spectrum at 365nm is tested on Edinburgh FLS 980 under the irradiation of X-rays (0.05Gy / h) .
[0044] figure 2 Represents the X-ray emission spectrum of the radiodynamic drug (Ir-M-1) with a double metal center described in Example 1 of the present invention and the iridium complex (Ir-2) that does not form a double metal center complex under solid .
[0045] In the figure: Ir-M-1 can be directly excited by X-rays in the solid state and emit red fluorescence, while Ir-2 hardly observes fluorescence emission;
[0046] From the above results, it can be seen that the bimetallic center structure involved in the present invention has better absorption of X-rays and higher energy transfer efficiency.
Embodiment 3
[0048] Verification of the Relative Generation of Hydroxyl Free Radicals (·OH) in Radiokinetic Drug (Ir-M-1) Aqueous Solutions under X-ray Irradiation:
[0049] 1. Prepare the Ir-2 and Ir-M-1 described in Example 1 into 1 mg / mL aqueous solution respectively, then add methylene blue with a final concentration of 0.25 mg / mL in the solution as a hydroxyl radical indicator, and use ultraviolet A spectrometer measures the absorbance of these solutions at 664 nm.
[0050] 2. After exposing the above solution to X-rays (0.25Gy), test the absorbance of the solution at 664nm again, and calculate the degradation rate of methylene blue.
[0051] like image 3 It means that the double metal center radiodynamic drug (Ir-M-1) described in Example 1 of the present invention and the iridium complex (Ir-2) that does not form a double metal center complex are irradiated by X-rays in an aqueous solution of the same concentration The relative generation content of hydroxyl radicals (·OH) is sho...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More - R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com



